Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients

Table 5

Adverse events, frequency, duration, disutility, and costs during trabectedin and ifosfamide treatment.

Adverse events	Frequency of patients (%)		Average duration (days)		Disutility value	Source	QALY loss		Cost per event	Source^†	Total costs
	Trabectedin	Ifosfamide	Trabectedin	Ifosfamide			Trabectedin	Ifosfamide			Trabectedin	Ifosfamide
Fatigue and asthenia	2.1	2.2	5.0	5.0	0.216	[12]	0.00006	0.00007	€153	[13]	€3	€3
Nausea	1.0	7.0	10.0	10.0	0.295	[12]	0.00008	0.00056	€1,464	[13]	€15	€120
Vomiting	2.1	5.3	7.5	7.5	0.295	[12]	0.00013	0.00032	€1,464	[13]	€31	€78
Anaemia	5.3	9.6	5.0	5.0	0.098	[14]	0.00007	0.00013	€1,864	[15]	€99	€179
Neutropenia	14.9	39.0	7.5	5.0	0.124	[16]	0.00038	0.00066	€1,329	[15]	€198	€518
Febrile neutropenia	4.3	19.7	12.5	13.0	0.124	[16]	0.00018	0.00087	€2,919	[15]	€6	€575
Thrombocytopenia	13.0	6.1	8.5	1.0	0.089	[17]	0.00027	0.00001	€3,503	[15]	€445	€214
Elevation of liver enzymes	44.7	0.0	3.0	0.0	0.089	#	0.00033	—	€153	[13]	€68	—
Alopecia	0.0	8.3	0.0	36.0	0.094	[16]	—	0.00077	€512	[18]	—	€42
Neurotoxicity	0.0	5.7	1.0	1.0	0.195	[12]	—	0.00003	€1,650	[13]	—	€94
Acute renal failure	0.0	1.8	0.0	16.0	0.124	[19]	—	0.00010	€1,593	[20]	—	€29
Catheter-related infection	2.1	0.1	3.0	0.0	0.161	[17]	0.00003	—	€5,920	[21]	€124	€6
					Total QALY loss		0.00153	0.00352	Total costs		€1,119	€1,841

Translated to Dutch utilities; ^†translated to 2018 costs in euro’s; ^#assumed similar to thrombocytopenia.